Gemini Therapeutics, Inc. (NASDAQ:GMTX – Get Free Report) shares hit a new 52-week high during trading on Tuesday . The stock traded as high as $51.04 and last traded at $50.92, with a volume of 159797 shares traded. The stock had previously closed at $50.77.
Gemini Therapeutics Stock Performance
The firm has a market capitalization of $2.21 billion, a price-to-earnings ratio of -50.77 and a beta of -0.12. The firm’s 50-day moving average price is $48.71 and its two-hundred day moving average price is $41.52.
About Gemini Therapeutics
Gemini Therapeutics, Inc, a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.
Featured Stories
- Five stocks we like better than Gemini Therapeutics
- Are Penny Stocks a Good Fit for Your Portfolio?
- How Verizon Could Offer Stress-Free Double-Digit Returns in 2025
- 3 Healthcare Dividend Stocks to Buy
- Can Roche Challenge Lilly and Novo in the Weight Loss Market?
- What is a Death Cross in Stocks?
- Roblox Stock: Key Metrics Surge, Is This the Perfect Entry?
Receive News & Ratings for Gemini Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemini Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
